Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced data for five of the Company’s innovative therapies for central nervous system (CNS) disorders will be presented at the 69th Annual Meeting of the American Academy of Neurology (AAN) in Boston, MA from April 22-28, 2017.

The accepted abstracts include data from Teva’s approved and pipeline products, with three platform and 16 poster presentations. Data for COPAXONE® (glatiramer acetate injection), a product for relapsing forms of multiple sclerosis (RMS); as well as Teva’s investigational therapies including deutetrabenazine tablets – formerly referred to as SD-809 – for the treatment of tardive dyskinesia (TD), laquinimod, being developed for relapsing and progressive forms of MS; pridopidine, under development for the treatment of Huntington’s disease (HD); and fremanezumab (TEV-48125), under development for the prevention of migraine, will be featured.

“Teva is dedicated to the ongoing evaluation of its therapies to ensure the delivery of safe and effective treatments for often under-recognized or difficult-to-treat CNS disorders,” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “The data to be presented at AAN highlight our continued progress and comprehensive research across our CNS portfolio in order to grow our understanding of the potential of our therapies, and continue delivering therapies to patients in need.”

The full set of Teva-sponsored data to be presented includes:

COPAXONE® (glatiramer acetate injection):

  • [P1.365] Pregnancy Outcomes in Patients with MS Exposed to Branded Glatiramer Acetate (Poster Session 1, April 23, 2017, 8:30 a.m. to 5:30 p.m.) P. Baruch, S. Melamed-Gal, S. Kolodny, O. Neudorfer
  • [P6.357] Predictors of Disability in Relapsing-Remitting Multiple Sclerosis (RRMS) During the Glatiramer Acetate Low-frequency Administration (GALA) Study (Poster Session 6, April 28, 2017, 8:30 a.m. to 5:30 p.m.) J. Alexander, D. Daudt, M.D. Davis, N. Ashtamker, S. Kolodny
  • [P3.401] Real-World Monitoring Costs Associated with Initiation of Disease-Modifying Therapy Among Patients with Multiple Sclerosis (Poster Session 4, April 25, 2017, 8:30 a.m. to 7:00 p.m.) M.J. Lage, Y. Wu
  • [P6.366] Comparison of Adherence and Persistence to Glatiramer Acetate 40 mg/mL Three-Times Weekly Subcutaneous Injections Versus Oral Therapies in Multiple Sclerosis (Poster Session 6, April 28, 2017, 8:30 a.m. to 5:30 p.m.) H. Trenz, D. Liassou, R. Wolbeck, R. Iyer, Y. Wu

Deutetrabenazine:

  • [P2.016] Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia (TD) (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) J. Jimenez-Shahed, H. Fernandez, D. Stamler, M.D. Davis, S. Factor, R. Hauser, J. Isojarvi, W. Ondo, K. Anderson
  • [P2.020] Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia (TD) as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) J. Jimenez-Shahed, H. Fernandez, D. Stamler, M.D. Davis, S. Factor, R. Hauser, J. Isojarvi, W. Ondo, K. Anderson
  • [S56.004] Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Improvements in Clinical Global Impression of Change (CGIC) with Deutetrabenazine Treatment in Moderate to Severe Tardive Dyskinesia (TD) (Platform Session 56, April 28, 2017, 4:06 to 4:18 p.m.) H. Fernandez, R. Hauser, M.D. Davis, S. Factor, J. Isojarvi, J. Jimenez-Shahed, W. Ondo, D. Stamler, K. Anderson
  • [S56.006] Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Effect of Fixed-Dose Deutetrabenazine by Baseline Comorbidities (Platform Session 56, April 28, 2017, 4:30 to 4:42 p.m.) K. Anderson, S. Factor, M.D. Davis, R. Hauser, J. Isojarvi, J. Jimenez-Shahed, D. Stamler, W. Ondo, H. Fernandez
  • [S56.007] Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Moderate to Severe Tardive Dyskinesia (TD) (Platform Session 56, April 28, 2017, 4:42 to 4:54 p.m.) K. Anderson, D. Stamler, M.D. Davis, S. Factor, R. Hauser, J. Isojarvi, J. Jimenez-Shahed, W. Ondo, H. Fernandez
  • [P2.018] Estimation of Epidemiology of Tardive Dyskinesia in the United States (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) A. Dhir, T. Schilling, V. Abler, R. Potluri, B. Carroll

Laquinimod:

  • [P2.353] Laquinimod modulates central nervous system inflammation via the aryl-hydrocarbon receptor and is effective in the chronic NOD progressive EAE model (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) J. Kaye, R. Laufer, J. Kenison, V. Rothhammer, F. J. Quintana
  • [P2.354] Disability Progression and Cerebrospinal Fluid Status in PPMS: Re-Analysis of the ProMiSe Clinical Trial Data Set (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) J.R. Steinerman, M.D. Davis, V. Knappertz, G. Giovannoni, J. Wolinsky
  • [P2.355] Laquinimod is a potent arylhydrocarbon receptor dependent activator of natural killer cells (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) E. Avendano-Guzman, M. Ott, C. Wegner, L. Hayardeny, E. Ullrich, M. Schoen, W. Brück, S. Nessler
  • [P2.365] Laquinimod targets the aryl hydrocarbon receptor (AhR) pathway in periphery and brains of naïve and EAE mice (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) T. Birnberg, J. Kaye, K.D. Fowler, B. Weiner, I.S. Caballero, S. Barash, E. Raymond, I. Ben-Eliezer, I. Fishbein, A. Orbach, D. Laifenfeld, R. Laufer, I. Grossman
  • [P2.366] Direct neuroprotective effect of laquinimod on glutamate excitotoxicity in experimental multiple sclerosis (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) F. De Vito, A. Musella, A. Gentile, S. Bullitta, D. Fresegna, F.R. Rizzo, G. Mandolesi, D. Centonze

Pridopidine:

  • [P2.005] Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results from the Phase II, Double-blind, Placebo-controlled, Dose-Ranging Study, Pride-HD (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) K. Kieburtz, G. Landwehrmeyer, R. Reilmann, J. Savola, E. Eyal, I. Grachev, B. Borowsky, A. McGarry, S. Papapetropoulos, M. Hayden
  • [P2.011] Effect of Pridopidine on Total Functional Capacity (TFC) in Huntington Disease (HD): A Comparison of Open-HART Subjects with Historical Placebo Controls (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) A. McGarry, V. Abler, P. Auinger, I. Grachev, S. Gandhi, S. Papapetropoulos
  • [P2.013] Implementation and Validation of a Biometric Solution for Remote Monitoring of Motor Symptoms in Patients with Huntington’s Disease in a Phase II Clinical Trial (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) S. Papapetropoulos, S. Fine, S. Taylor, K. Blatt, E. Cohen, C. Admati, Y. Dolan, J. Lemieux, I. Grachev, I. Grossman, M. Hayden

Fremanezumab (TEV-48125):

  • [P2.159] What does the humanized monoclonal anti-CGRP antibody (TEV-48125) teach us about the perception of migraine headache? (Poster Session 2, April 24, 2017, 8:30 a.m. to 7:00 p.m.) A. Melo-Carrillo, A. Strassman, A. Schain, R. Reuven-Nir, R. Burstein

About COPAXONE®

COPAXONE® (glatiramer acetate injection) is indicated for the treatment of patients with relapsing forms of multiple sclerosis. The most common side effects of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. See additional important information at: www.CopaxonePrescribingInformation.com. For hardcopy releases, please see enclosed full prescribing information. COPAXONE® is approved in more than 50 countries worldwide, including the United States, Russia, Canada, Mexico, Australia, Israel, and all European countries.

Leave a Reply

Your email address will not be published.

X